Vaxcyte, Inc.
PCVX
$31.16
-$0.29-0.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -140.72M | -137.08M | -103.12M | -128.70M | -95.02M |
| Total Depreciation and Amortization | 4.87M | 4.79M | 4.49M | 3.48M | 3.09M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.09M | 23.38M | 8.71M | 11.62M | 6.64M |
| Change in Net Operating Assets | -49.52M | -2.49M | 29.22M | -7.79M | -73.83M |
| Cash from Operations | -166.27M | -111.40M | -60.71M | -121.39M | -159.12M |
| Capital Expenditure | -26.75M | -30.03M | -38.08M | -38.98M | -12.07M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 150.07M | -527.14M | -878.94M | -41.43M | -439.00M |
| Cash from Investing | 123.32M | -557.17M | -917.02M | -80.41M | -451.07M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6.05M | 5.99M | 1.52B | 110.93M | 821.50M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.29M | -1.09M | -9.34M | -565.00K | -3.31M |
| Cash from Financing | 759.00K | 4.91M | 1.52B | 110.37M | 818.20M |
| Foreign Exchange rate Adjustments | 1.17M | 1.35M | -5.58M | -1.41M | 6.06M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -41.03M | -662.31M | 531.73M | -92.84M | 214.06M |